Chara Stavraka

Employment

• King's College London NIHR Clinical Lecturer
  2021 - 2022
• Guy's and Saint Thomas' NHS Foundation Trust NIHR Academic Clinical Fellow & Specialist Registrar
  2017 - 2021
• Imperial College London CRUK Clinical Research Fellow
  2014 - 2017
• Norfolk and Norwich University Hospital Core Medical Trainee
  2012 - 2014
• Imperial College Healthcare NHS Trust Clinical Research Fellow
  2010 - 2012
• King's College London
  ? - 2022

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (54)

• Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha
  Chara Stavraka, Jitesh Chauhan, Silvia Crescioli +26 more
  Allergy 2025 DOI: 10.1111/all.16514
  +Save
• Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction
  Gabriel Osborn, Jacobo López‐Abente, Rebecca Adams +25 more
  Nature Communications 2025 DOI: 10.1038/s41467-025-57870-y
  +Save
• Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production
  Heather J. Bax, Jitesh Chauhan, Alexandra J. McCraw +17 more
  Mabs 2025 DOI: 10.1080/19420862.2025.2451295
  +Save
• Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha
  James F. Spicer, Bristi Basu, Ana Montes +29 more
  Nature Communications 2023 DOI: 10.1038/s41467-023-39679-9
  +Save
• Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4
  Jitesh Chauhan, Melanie Grandits, Lais C. G. F. Palhares +37 more
  Nature Communications 2023 DOI: 10.1038/s41467-023-37811-3
  +Save
• Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
  Nature medicine 2023 DOI: 10.1038/s41591-023-02240-8
  +Save
• Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
  Heather J. Bax, Jitesh Chauhan, Chara Stavraka +33 more
  British Journal of Cancer 2023 DOI: 10.1038/s41416-022-02031-x
  +Save
• Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study
  Cancers 2022 DOI: 10.3390/cancers14246056
  +Save
• Characteristics and survival of advanced non-small cell lung cancer (NSCLC) in young Black patients: a Guy’s Cancer Centre real-world study.
  2022
  +Save
• Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies
  Clinical and Experimental Immunology 2022 DOI: 10.1093/cei/uxab020
  +Save
• Clinical and Translational Significance of Basophils in Patients with Cancer
  Jitesh Chauhan, Chara Stavraka, Melanie Grandits +6 more
  Cells 2022 DOI: 10.3390/cells11030438
  +Save
• Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors
  Clinical Colorectal Cancer 2021 DOI: 10.1016/j.clcc.2021.09.009
  +Save
• Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments
  Alex J. McCraw, Jitesh Chauhan, Heather J. Bax +10 more
  Cancers 2021 DOI: 10.3390/cancers13174460
  +Save
• The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
  ANNALS OF TRANSLATIONAL MEDICINE 2021 DOI: 10.21037/atm-20-6427
  +Save
• Trial in progress: Combination of the dual RAF/MEK inhibitor VS-6766 with the mTOR inhibitor everolimus with expansion in patients with KRAS mutant NSCLC
  Trial in progress: Combination of the dual RAF/MEK inhibitor VS-6766 with the mTOR inhibitor everolimus with expansion in patients with KRAS mutant NSCLC 2021
  +Save
• IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype
  Mano Nakamura, Elmira Amiri Souri, Gabriel Osborn +17 more
  Cancers 2020 DOI: 10.3390/cancers12113376
  +Save
• Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
  Cancers 2020 DOI: 10.3390/cancers12113370
  +Save
• Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations
  Frontiers in Oncology 2020 DOI: 10.3389/fonc.2020.553080
  +Save
• IgE Antibodies against Cancer: Efficacy and Safety
  Jitesh Chauhan, Alex J. McCraw, Mano Nakamura +8 more
  Antibodies 2020 DOI: 10.3390/antib9040055
  +Save
• Impact of Chromosome 9 Numerical Imbalances in Oral Squamous Cell Carcinoma: A Pilot Grid-Based Centromere Analysis
  Diagnostics 2020 DOI: 10.3390/diagnostics10070501
  +Save